NO3137093T3 - - Google Patents

Info

Publication number
NO3137093T3
NO3137093T3 NO15720059A NO15720059A NO3137093T3 NO 3137093 T3 NO3137093 T3 NO 3137093T3 NO 15720059 A NO15720059 A NO 15720059A NO 15720059 A NO15720059 A NO 15720059A NO 3137093 T3 NO3137093 T3 NO 3137093T3
Authority
NO
Norway
Application number
NO15720059A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3137093T3 publication Critical patent/NO3137093T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
NO15720059A 2014-04-29 2015-04-29 NO3137093T3 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14166355 2014-04-29
EP14166354 2014-04-29
PCT/EP2015/059339 WO2015165966A1 (fr) 2014-04-29 2015-04-29 Traitement et prévention de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
NO3137093T3 true NO3137093T3 (fr) 2018-02-10

Family

ID=53039896

Family Applications (1)

Application Number Title Priority Date Filing Date
NO15720059A NO3137093T3 (fr) 2014-04-29 2015-04-29

Country Status (18)

Country Link
US (1) US10478454B2 (fr)
EP (2) EP3137093B1 (fr)
JP (1) JP6692755B2 (fr)
KR (1) KR102388363B1 (fr)
CN (1) CN106659738B (fr)
AU (1) AU2015254663B2 (fr)
CA (1) CA2946928C (fr)
CY (1) CY1119674T1 (fr)
DK (1) DK3137093T3 (fr)
ES (2) ES2651537T3 (fr)
HR (1) HRP20171896T1 (fr)
HU (1) HUE037501T2 (fr)
LT (1) LT3137093T (fr)
NO (1) NO3137093T3 (fr)
PL (1) PL3137093T3 (fr)
PT (1) PT3137093T (fr)
SI (1) SI3137093T1 (fr)
WO (1) WO2015165966A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11065273B2 (en) 2014-04-29 2021-07-20 Affiris Ag Treatment and prevention of alzheimer's disease (AD)
US10646565B2 (en) 2014-04-29 2020-05-12 Affiris Ag Treatment of alzheimer'S disease (AD) with an aluminum salt

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016327A1 (fr) * 1993-01-14 1994-07-21 Pollard Harvey B Procedes et compositions pour bloquer les canaux ioniques des proteines amyloïdes
BR9814945A (pt) * 1997-08-21 2000-09-05 Gerolymatos P N Sa Utilização de fanquinona para o tratamento de doença de alzheimer, composição farmacêutica e kit
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
PE20130642A1 (es) * 2010-03-29 2013-06-19 Novartis Ag Composicion que comprende el peptido amiloide beta 1-6 acoplado a una particula similar a virus y un auxiliar

Also Published As

Publication number Publication date
JP2017518275A (ja) 2017-07-06
ES2651537T3 (es) 2018-01-29
EP3269376B1 (fr) 2020-07-15
LT3137093T (lt) 2017-12-11
CN106659738B (zh) 2021-02-09
KR102388363B1 (ko) 2022-04-19
US20170049812A1 (en) 2017-02-23
PT3137093T (pt) 2017-12-19
AU2015254663B2 (en) 2020-04-02
EP3269376A1 (fr) 2018-01-17
CA2946928C (fr) 2023-01-31
DK3137093T3 (en) 2017-12-11
US10478454B2 (en) 2019-11-19
CN106659738A (zh) 2017-05-10
HRP20171896T1 (hr) 2018-02-23
EP3137093A1 (fr) 2017-03-08
ES2824763T3 (es) 2021-05-13
WO2015165966A1 (fr) 2015-11-05
SI3137093T1 (en) 2018-01-31
CY1119674T1 (el) 2018-04-04
PL3137093T3 (pl) 2018-06-29
CA2946928A1 (fr) 2015-11-05
EP3137093B1 (fr) 2017-09-13
AU2015254663A1 (en) 2016-11-10
HUE037501T2 (hu) 2018-08-28
KR20160145822A (ko) 2016-12-20
JP6692755B2 (ja) 2020-05-13

Similar Documents

Publication Publication Date Title
BR112016027844A2 (fr)
RU2016138570A3 (fr)
BR112016010711A2 (fr)
BR112016027506A2 (fr)
BR112016025771A2 (fr)
BR112016013819A2 (fr)
JP1536339S (fr)
BR112016015243A2 (fr)
BR112016026639A2 (fr)
BR112016019382A2 (fr)
BR112016020283A2 (fr)
BR112016016798A2 (fr)
RU2015113431A3 (fr)
BR112016015133A2 (fr)
BR112016030540A2 (fr)
BR112016015632A2 (fr)
RU2016133992A3 (fr)
BR112016021960A2 (fr)
TWI512655B (fr)
BR112016021297A2 (fr)
BR112016019130A2 (fr)
BR112016018822A2 (fr)
BR112016012481A2 (fr)
BR112016018978A2 (fr)
JP1522076S (fr)